{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:47:16Z","timestamp":1768340836950,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.amjcard.2016.10.027","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T20:16:42Z","timestamp":1478031402000},"page":"397-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)"],"prefix":"10.1016","volume":"119","author":[{"given":"Lori","family":"Mosca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Guyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Ralph T.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2016.10.027_bib1","doi-asserted-by":"crossref","first-page":"3H","DOI":"10.1016\/0002-9149(92)91083-G","article-title":"Epidemiology of triglycerides: a view from Framingham","volume":"70","author":"Castelli","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.10.027_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2016.10.027_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J\u00a0Cardiovasc Risk"},{"key":"10.1016\/j.amjcard.2016.10.027_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/STROKEAHA.111.641324","article-title":"Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women","volume":"43","author":"Berger","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2016.10.027_bib5","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2008.621","article-title":"Nonfasting triglycerides and risk of ischemic stroke in the general population","volume":"300","author":"Freiberg","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2016.10.027_bib6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/CIR.0b013e31820faaf8","article-title":"Effectiveness-based guidelines for the prevention of cardiovascular disease in women\u20142011 update: a guideline from the American Heart Association","volume":"123","author":"Mosca","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.10.027_bib7","series-title":"Women's Health Research: Progress, Pitfalls, and Promise","first-page":"1","year":"2010"},{"key":"10.1016\/j.amjcard.2016.10.027_bib8","series-title":"Vascepa [package Insert]","year":"2016"},{"key":"10.1016\/j.amjcard.2016.10.027_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.10.027_bib10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.10.027_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-012-0002-3","article-title":"Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies","volume":"13","author":"Bays","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2016.10.027_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2016.10.027_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.plefa.2013.07.005","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)","volume":"89","author":"Braeckman","year":"2013","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.amjcard.2016.10.027_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpdd.84","article-title":"Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects","volume":"3","author":"Braeckman","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.amjcard.2016.10.027_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacl.2016.02.008","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies","volume":"10","author":"Ballantyne","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.amjcard.2016.10.027_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2016.08.005","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies","volume":"253","author":"Ballantyne","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2016.10.027_bib17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2016.10.027_bib18","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.10.027_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/met.2011.0004","article-title":"Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database","volume":"9","author":"Zargar","year":"2011","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.amjcard.2016.10.027_bib20","first-page":"46","article-title":"Prescription omega-3 fatty acid products and dietary supplements are not interchangeable","author":"Hilleman","year":"2016","journal-title":"Manag Care"},{"key":"10.1016\/j.amjcard.2016.10.027_bib21","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/jsfa.6816","article-title":"A\u00a0comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States","volume":"95","author":"Kleiner","year":"2015","journal-title":"J\u00a0Sci Food Agric"},{"key":"10.1016\/j.amjcard.2016.10.027_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.plefa.2013.01.001","article-title":"Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: participation of cholesterol ester transfer protein and LDL receptor","volume":"88","author":"Ishida","year":"2013","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.amjcard.2016.10.027_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jnutbio.2011.03.004","article-title":"Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men","volume":"23","author":"Dawson","year":"2012","journal-title":"J\u00a0Nutr Biochem"},{"key":"10.1016\/j.amjcard.2016.10.027_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","article-title":"Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review","volume":"6","author":"Jacobson","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.amjcard.2016.10.027_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.prostaglandins.2016.07.007","article-title":"Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies","volume":"125","author":"Bays","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.amjcard.2016.10.027_bib26","unstructured":"A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). ClinicalTrials gov: Available at: https:\/\/clinicaltrials.gov\/show\/NCT01492361. Accessed on August 31,\u00a02016."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916317386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916317386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T02:23:47Z","timestamp":1536287027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914916317386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0002914916317386"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.10.027","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}